Pharmaceutical giant GSK has revealed it has settled a lawsuit relating to discontinued heartburn drug Zantac, which was alleged to be linked to cancer.
Shares in GSK jumped after it said an upcoming trial was cancelled but that it does not admit liability.
The company hit back at allegations last year that the use of Zantac, known chemically as ranitidine, increases the risk of cancer in patients.
